Cargando…
Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia
The increasing incidence of pregnancy complications, particularly gestational diabetes mellitus (GDM) and preeclampsia (PE), is a cause for concern, as they can result in serious health consequences for both mothers and infants. The pathogenesis of these complications is still not fully understood,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255128/ https://www.ncbi.nlm.nih.gov/pubmed/37299422 http://dx.doi.org/10.3390/nu15112459 |
_version_ | 1785056796956688384 |
---|---|
author | Qin, Yushu Bily, Donalyn Aguirre, Makayla Zhang, Ke Xie, Linglin |
author_facet | Qin, Yushu Bily, Donalyn Aguirre, Makayla Zhang, Ke Xie, Linglin |
author_sort | Qin, Yushu |
collection | PubMed |
description | The increasing incidence of pregnancy complications, particularly gestational diabetes mellitus (GDM) and preeclampsia (PE), is a cause for concern, as they can result in serious health consequences for both mothers and infants. The pathogenesis of these complications is still not fully understood, although it is known that the pathologic placenta plays a crucial role. Studies have shown that PPARγ, a transcription factor involved in glucose and lipid metabolism, may have a critical role in the etiology of these complications. While PPARγ agonists are FDA-approved drugs for Type 2 Diabetes Mellitus, their safety during pregnancy is not yet established. Nevertheless, there is growing evidence for the therapeutic potential of PPARγ in the treatment of PE using mouse models and in cell cultures. This review aims to summarize the current understanding of the mechanism of PPARγ in placental pathophysiology and to explore the possibility of using PPARγ ligands as a treatment option for pregnancy complications. Overall, this topic is of great significance for improving maternal and fetal health outcomes and warrants further investigation. |
format | Online Article Text |
id | pubmed-10255128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102551282023-06-10 Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia Qin, Yushu Bily, Donalyn Aguirre, Makayla Zhang, Ke Xie, Linglin Nutrients Review The increasing incidence of pregnancy complications, particularly gestational diabetes mellitus (GDM) and preeclampsia (PE), is a cause for concern, as they can result in serious health consequences for both mothers and infants. The pathogenesis of these complications is still not fully understood, although it is known that the pathologic placenta plays a crucial role. Studies have shown that PPARγ, a transcription factor involved in glucose and lipid metabolism, may have a critical role in the etiology of these complications. While PPARγ agonists are FDA-approved drugs for Type 2 Diabetes Mellitus, their safety during pregnancy is not yet established. Nevertheless, there is growing evidence for the therapeutic potential of PPARγ in the treatment of PE using mouse models and in cell cultures. This review aims to summarize the current understanding of the mechanism of PPARγ in placental pathophysiology and to explore the possibility of using PPARγ ligands as a treatment option for pregnancy complications. Overall, this topic is of great significance for improving maternal and fetal health outcomes and warrants further investigation. MDPI 2023-05-25 /pmc/articles/PMC10255128/ /pubmed/37299422 http://dx.doi.org/10.3390/nu15112459 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Qin, Yushu Bily, Donalyn Aguirre, Makayla Zhang, Ke Xie, Linglin Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia |
title | Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia |
title_full | Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia |
title_fullStr | Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia |
title_full_unstemmed | Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia |
title_short | Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia |
title_sort | understanding pparγ and its agonists on trophoblast differentiation and invasion: potential therapeutic targets for gestational diabetes mellitus and preeclampsia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255128/ https://www.ncbi.nlm.nih.gov/pubmed/37299422 http://dx.doi.org/10.3390/nu15112459 |
work_keys_str_mv | AT qinyushu understandingpparganditsagonistsontrophoblastdifferentiationandinvasionpotentialtherapeutictargetsforgestationaldiabetesmellitusandpreeclampsia AT bilydonalyn understandingpparganditsagonistsontrophoblastdifferentiationandinvasionpotentialtherapeutictargetsforgestationaldiabetesmellitusandpreeclampsia AT aguirremakayla understandingpparganditsagonistsontrophoblastdifferentiationandinvasionpotentialtherapeutictargetsforgestationaldiabetesmellitusandpreeclampsia AT zhangke understandingpparganditsagonistsontrophoblastdifferentiationandinvasionpotentialtherapeutictargetsforgestationaldiabetesmellitusandpreeclampsia AT xielinglin understandingpparganditsagonistsontrophoblastdifferentiationandinvasionpotentialtherapeutictargetsforgestationaldiabetesmellitusandpreeclampsia |